shutterstock_1424208956.jpg

Multi-Specific NK Engager Antibodies

Our fully owned patented plug-and-play multi-specific antibody platform allows for the rapid development of multiple drug candidates. The platform has been initially validated by a pan-academic consortium and is currently further developed at our partner development and GMP manufacturing facility near Boston, MA. 

We are developing a proprietary tri-functional format for enhanced efficacy. We are focused on NK engager bi-specific and multi-specific antibodies for the treatment of hematological cancers such and  solid tumors.


Cytovia is developing NKp46 multifunctional engagers with the potential for better disease control without hurting the healthy cells.

 

Subscribe Form

  • Facebook
  • Twitter
  • LinkedIn